Treatment‐free remission with first‐ and second‐generation tyrosine kinase inhibitors

Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase

(2018) François-Xavier Mahon et al.   ANNALS OF INTERNAL MEDICINE

Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment

(2018) Masaya Okada et al.   Clinical Lymphoma Myeloma & Leukemia

Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study

(2018) David M. Ross et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

(2018) Susanne Saussele et al.   LANCET ONCOLOGY

Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study

(2017) Delphine Rea et al.   HAEMATOLOGICA

Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia

(2017) Gabriel Etienne et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study

(2017) A Hochhaus et al.   LEUKEMIA

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

(2017) Andreas Hochhaus et al.   NEW ENGLAND JOURNAL OF MEDICINE

Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study

(2017) Delphine Rea et al.   HAEMATOLOGICA

De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial

(2017) Richard E Clark et al.   Lancet Haematology

Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study

(2016) Delphine Rea et al.   BLOOD

Moving treatment-free remission into mainstream clinical practice in CML

(2016) Timothy P. Hughes et al.   BLOOD

Adherence to Monitoring Tests in Patients With Chronic Myeloid Leukemia in Lebanon

(2016) Marcel Massoud et al.   Clinical Lymphoma Myeloma & Leukemia

Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study

(2016) S.-E. Lee et al.   HAEMATOLOGICA

Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial

(2016) Jorge E. Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population

(2016) Hannah Bower et al.   JOURNAL OF CLINICAL ONCOLOGY

The concept of treatment-free remission in chronic myeloid leukemia

(2016) S Saußele et al.   LEUKEMIA

Measurement of BCR-ABL1 transcripts on the International Scale in the United States: current status and best practices

(2016) Ranjana Arora et al.   LEUKEMIA & LYMPHOMA

Rationale and Protocol of CML Study: Cognitive and Emotional Impact of Discontinuation of Therapy in Patients with Chronic Myeloid Leukemia

(2016) Silvia Riva et al.   TUMORI

Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study

(2016) S.-E. Lee et al.   HAEMATOLOGICA

Rationale and Protocol of CML Study: Cognitive and Emotional Impact of Discontinuation of Therapy in Patients with Chronic Myeloid Leukemia

(2016) Silvia Riva et al.   TUMORI JOURNAL

The impact of dasatinib on pregnancy outcomes

(2015) Jorge E. Cortes et al.   AMERICAN JOURNAL OF HEMATOLOGY

Clinical features of pulmonary arterial hypertension in patients receiving dasatinib

(2015) Neil P. Shah et al.   AMERICAN JOURNAL OF HEMATOLOGY

Pediatric chronic myeloid leukemia is a unique disease that requires a different approach

(2015) N. Hijiya et al.   BLOOD

Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia

(2015) N C P Cross et al.   LEUKEMIA

Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients

(2015) Massimo Breccia et al.   LEUKEMIA RESEARCH

Cost-Effectiveness Of Nilotinib In Patients With Chronic Myeloid Leukaemia Eligible To Start The Treatment-Free Remission Phase In Italy

(2015) A Aiello et al.   VALUE IN HEALTH

Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials

(2015) Koji Sasaki et al.   Lancet Haematology

Treatment-free remission after imatinib discontinuation is possible in paediatric patients with chronic myeloid leukaemia

(2014) Fiorina Giona et al.   BRITISH JOURNAL OF HAEMATOLOGY

Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)

(2014) Henrik Hjorth-Hansen et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Discontinuation of Imatinib: A Tyrosine Kinase Inhibitor Withdrawal Syndrome?

(2014) Johan Richter et al.   JOURNAL OF CLINICAL ONCOLOGY

TYROSINE KINASE INHIBITORS AND PREGNANCY

(2014) Elisabetta Abruzzese et al.   Mediterranean Journal of Hematology and Infectious Diseases

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

(2013) M. Baccarani et al.   BLOOD

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

(2013) D. M. Ross et al.   BLOOD

Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: A randomised trial of the Dutch–Belgian Cooperative Trial for Haemato-Oncology (HOVON)

(2013) Noortje Thielen et al.   EUROPEAN JOURNAL OF CANCER

Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV

(2013) Rüdiger Hehlmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease

(2013) Philippe Rousselot et al.   JOURNAL OF CLINICAL ONCOLOGY

Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia

(2013) Stacie B. Dusetzina et al.   JOURNAL OF CLINICAL ONCOLOGY

Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience

(2013) Ohad Benjamini et al.   LEUKEMIA & LYMPHOMA

Imatinib cessation in children and adolescents with chronic myeloid leukemia in chronic phase

(2013) Frédéric Millot et al.   PEDIATRIC BLOOD & CANCER

Second attempt to discontinue imatinib in CP-CML patients with a second sustained complete molecular response

(2012) L. Legros et al.   BLOOD

Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response

(2012) Ho-Young Yhim et al.   LEUKEMIA RESEARCH

Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population

(2011) F. Efficace et al.   BLOOD

Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay

(2011) Hyun-Gyung Goh et al.   LEUKEMIA & LYMPHOMA

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

(2010) François-Xavier Mahon et al.   LANCET ONCOLOGY

The effects of imatinib on pregnancy outcome

(2008) S. M. Pye et al.   BLOOD